Jim Glasheen    GENERAL PARTNER

Jim has been with Technology Partners since 2002.  Jim leads the firm's efforts in Consumer Medicine, investing in both medical device and biopharmaceutical companies.

He serves on the boards of ElCelyx, Essentialis, ForSight VISION5, Revance Therapeutics (RVNC), Transcend Medical, and TRIA Beauty, while also having led Technology Partners' investment in companies that have since been acquired: Iomai (IOMI - acquired by Intercell AG), Cadence Pharmaceuticals (CADX - acquired by Mallinkrodt), Incline Therapeutics (acquired by The Medicines Company - MDCO).  Jim is also an advisor to the Lester Center at University of California, Berkeley and the National Science Foundation (NSF) in Washington, DC.

Previously, Jim was Managing Director at CIT Venture Capital, leading the group's effort in Life Science investing.  Also, Jim was a leader within McKinsey & Company's Pharmaceutical and Medical Products Practice.  Jim earned a BS from Duke University and an MA and a PhD from Harvard University in biology.  He was a Deutsche Akademische Austauschdienst (DAAD) fellow at Universitaet des Saarlandes, Germany and a post-doctoral fellow at University of California, Berkeley.  Jim has published several research papers and had his research highlighted in major media outlets including: Nature, The New York Times, Scientific American, and CNN.

Jim can be reached at:

jim@technologypartners.com




Copyright© 2008 - 2012 Technology Partners. All rights reserved. SITE MAP